MAPK
MAPKs are a family of protein kinases involved in a variety of cellular processes, including growth, proliferation, differentiation, and stress responses. The MAPK signaling pathway consists of several tiers, including ERK, JNK, and p38 MAPKs, each playing distinct roles in cellular function. Dysregulation of MAPK signaling is linked to cancer, inflammatory diseases, and metabolic disorders. At CymitQuimica, we offer a wide array of MAPK inhibitors and activators to support your research in cell biology, signal transduction, and disease mechanisms.
Found 885 products of "MAPK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
pan-KRAS-IN-2
CAS:<p>Pan-KRAS-IN-2 (compound 6) is a broad-spectrum KRAS inhibitor exhibiting potent activity with IC50 values of ≤10 nM against KRAS wild type and its mutants (G12D</p>Formula:C34H34F2N4O3Purity:98%Color and Shape:SolidMolecular weight:584.66SB-682330A
CAS:<p>SB-682330A is a Raf kinase inhibitor.</p>Formula:C28H27N3O3Color and Shape:SolidMolecular weight:453.53TC13172
CAS:<p>TC13172 is a potent, covalent MLKL inhibitor, selective over RIPK1/RIPK3. It blocks TSZ-induced necroptosis (EC50=2nM) and MLKL oligomerization at 100nM.</p>Formula:C17H16N4O5SPurity:98%Color and Shape:SolidMolecular weight:388.4KRAS degrader-1
CAS:<p>KRAS degrader-1 (compound 1) is a potent agent that selectively targets KRAS proteins for destruction via the autophagy-lysosomal degradation pathway [1].</p>Formula:C55H57Br2ClFIN8O7Color and Shape:SolidMolecular weight:1283.25Cobimetinib racemate
CAS:<p>Cobimetinib racemate (Cobimetinib (racemate)) (GDC-0973 racemate) is a selective inhibitor of MEK.Cobimetinib racemate is also known as a mitogen-activated</p>Formula:C21H21F3IN3O2Purity:98.00% - 99.71%Color and Shape:SolidMolecular weight:531.31Kras binder 12
CAS:<p>Kras binder 12 can be used in studies about Ras.</p>Formula:C29H47N9O6Color and Shape:SoildMolecular weight:617.74ARQ-736
CAS:<p>ARQ 736 effectively targets and inhibits BRAF, crucial in MAPK pathway, beneficial for treating melanomas and certain colon cancers.</p>Formula:C25H25N8Na2O8PSColor and Shape:SolidMolecular weight:674.54Ilaprazole sodium hydrate
CAS:<p>Ilaprazole sodium hydrate (IY-81149 sodium hydrate) is a proton pump inhibitor that blocks the transport of HSV particles.</p>Formula:C19H21N4NaO4SPurity:99.2%Color and Shape:SolidMolecular weight:424.45KRAS G12C inhibitor 17
CAS:<p>KRAS G12C inhibitor 17 is a potent KRAS G12C inhibitor.</p>Formula:C24H20ClF2N3O3Purity:98%Color and Shape:SolidMolecular weight:471.88ARS-1323-alkyne
CAS:<p>ARS-1323-alkyne is a switch-II pocket (S-IIP) inhibitor and a conformational specific chemical reporter of KRASG12C nucleotide state in living cells.</p>Formula:C28H27ClF2N6O3Purity:98.00% - 99%Color and Shape:SolidMolecular weight:569ERK1/2 inhibitor 5
CAS:<p>ERK1/2 inhibitor 5: potent against ERK1/2, may combat cancer and inflammation.</p>Formula:C28H32ClFN6O5Color and Shape:SolidMolecular weight:587.04ARS-1323
CAS:<p>ARS-1323 is the racemate of ARS-1620 and a mutant K-ras G12C inhibitor.</p>Formula:C21H17ClF2N4O2Purity:99.53%Color and Shape:SolidMolecular weight:430.84KRAS G12C inhibitor 32
CAS:<p>KRAS G12C Inhibitor 32, an eight-membered heterocyclic compound with nitrogen, acts as a potent inhibitor of KRAS G12C [1].</p>Formula:C29H30Cl3FN6O3Purity:98%Color and Shape:SolidMolecular weight:635.94TH-Z827
CAS:<p>TH-Z827 is a mutant-selective inhibitor targeting KRAS(G12D) with an IC50 of 2.4 μM, demonstrating specificity by not binding to KRAS(WT) or KRAS(G12C).</p>Formula:C30H38N6OPurity:98%Color and Shape:SolidMolecular weight:498.66HPK1-IN-9
CAS:<p>HPK1-IN-9: Potent MAP4K family kinase inhibitor targeting hematopoietic progenitor cells; potential in HPK1 diseases. (Patent WO2021213317A1)</p>Formula:C30H33N7O2Color and Shape:SolidMolecular weight:523.63CHI-000-667
CAS:<p>CHI-000-667 can be used in studies about Ras.</p>Formula:C21H16ClNO4SColor and Shape:SolidMolecular weight:413.87KRAS G12C inhibitor 28
CAS:<p>KRAS G12C Inhibitor 28 is a compound that effectively inhibits the KRAS G12C mutation, exhibiting potent antitumor effects with an inhibitory concentration (</p>Formula:C33H36F2N5O4PColor and Shape:SolidMolecular weight:635.64K-Ras G12C-IN-2
CAS:<p>K-Ras G12C-IN-2 is a covalent kras g12c inhibitor.</p>Formula:C21H27ClN4O3Purity:98%Color and Shape:SolidMolecular weight:418.92SHP2-IN-22
CAS:<p>SHP2-IN-22, a potent SHP2 allosteric inhibitor, exhibits an IC50 value of 17.7 nM and effectively suppresses proliferation, migration, and invasion in MIA PaCa-</p>Formula:C23H22Cl2N8OColor and Shape:SolidMolecular weight:497.38KRAS G12C inhibitor 40
CAS:<p>KRAS G12C inhibitor 40 targets KRAS G12C in cancer research (WO2021129824A1, compound 70).</p>Formula:C34H36ClFN10O2Color and Shape:SolidMolecular weight:671.17HPK1 antagonist-1
CAS:<p>HPK1 antagonist-1 (I-792) is an inhibitor targeting HPK1, with potential applications in cancer and immune disease research [1].</p>Formula:C28H29FN6O2Color and Shape:SolidMolecular weight:500.57Exarafenib
CAS:<p>Exarafenib (RAF/KIN_2787) is an oral pan-RAF inhibitor with antitumor properties, targeting MAPK signaling in cancer research.</p>Formula:C26H34F3N5O3Purity:98.36% - 99.84%Color and Shape:SolidMolecular weight:521.58Kras4B G12D-IN-1
CAS:<p>Kras4B G12D-IN-1 is an inhibitor of Kras4B G12D with anticancer activity.Kras4B G12D-IN-1 inhibits Kras protein expression.</p>Formula:C16H21ClN2O4SPurity:99.75%Color and Shape:SolidMolecular weight:372.87HG6-64-1
CAS:<p>HG6-64-1 (HMSL 10017-101-1, compound 9 (XI-1)) is a potent and selective B-Raf inhibitor with an IC50 = 0.09 μM in B-raf V600E-transformed Ba/F3 cells.</p>Formula:C32H34F3N5O2Purity:99.89%Color and Shape:SolidMolecular weight:577.64ZYF0033
CAS:<p>ZYF0033(HPK1-IN-22) is an orally effective inhibitor of HPK1 that inhibits the phosphorylation of MBP proteins and decreases the phosphorylation of SLP76.</p>Formula:C26H30N4O2SPurity:99.70%Color and Shape:SolidMolecular weight:462.61JWG-071
CAS:<p>JWG-071: First ERK5 kinase probe, BET inhibitor, 1 μM BRD4 IC, boosts ERK5 function and BRD4 selectivity.</p>Formula:C34H44N8O3Purity:98.33%Color and Shape:SolidMolecular weight:612.77BI-2493
CAS:<p>BI-2493 is a highly selective pan-KRAS inhibitor and structural analog of BI-2865.BI-2493 exhibits antitumor activity and inhibits tumor cell growth.Cost-effective and quality-assured.</p>Formula:C24H27N7OSPurity:97.74% - 99.88%Color and Shape:SoildMolecular weight:461.58Pan-RAS-IN-1
CAS:<p>Pan-RAS-IN-1 is an inhibitor of pan-Ras. It disrupts the interaction of Ras proteins and their effectors.</p>Formula:C36H41Cl2F3N6O2Purity:99.77%Color and Shape:SolidMolecular weight:717.65MK-8353
CAS:<p>MK-8353 (SCH900353) is a potent, selective and orally available inhibitor of ERK1/2 (IC50s of 23.0 nM and 8.8 nM, respectively)</p>Formula:C37H41N9O3SPurity:96.15% - 97.19%Color and Shape:SolidMolecular weight:691.84KRAS G12C inhibitor 50
CAS:<p>KRAS G12C inhibitor 50 is a KRAS G12C inhibitor (IC50: 46.7 nM).</p>Formula:C31H34N8O2Color and Shape:SolidMolecular weight:550.65MK2-IN-4
CAS:<p>MK2-IN-4 is a MAPKAPK2 (MK2) inhibitor (IC50: 45 nM). MK2-IN-4 can be used in cancer, inflammation and immunology studies.</p>Formula:C25H24N4O2Color and Shape:SolidMolecular weight:412.48KRAS inhibitor-36
CAS:<p>KRAS inhibitor-36 (compound Abd2) directly inhibits KRAS Q61H.</p>Formula:C14H13NO4Color and Shape:SolidMolecular weight:259.26KRASG12C IN-12
CAS:<p>KRASG12C IN-12 (compound-1) acts as an inhibitor of KRASG12C. It forms a ternary complex with intracellular CYPA and the activated mutant of KRASG12C.</p>Formula:C29H39N5O6S2Color and Shape:SolidMolecular weight:617.78KRAS G12D inhibitor 19
CAS:<p>KRAS G12D inhibitor 19 (Compound 7) is used in cancer research [1]. As a specific inhibitor of KRAS G12D, it targets and potentially suppresses this mutation, which is frequently associated with various cancers.</p>Formula:C35H34F2N6O3Color and Shape:SolidMolecular weight:624.68AZD4625
<p>AZD4625 (Compound 21) is a selective, potent, orally active, covalent and mutagenic mutant GTPaseKRASG12C inhibitor.</p>Formula:C24H21ClF2N4O3Color and Shape:SolidMolecular weight:486.9KRAS ligand 3
CAS:<p>KRAS ligand 3 (compound 1), a BTX-6654 target-binding ligand, exhibits synergistic tumor growth inhibition through its capacity to bind a KRAS inhibitor [1].</p>Formula:C24H28F3N5Color and Shape:SolidMolecular weight:443.51PAT-IN-1
CAS:<p>PAT-IN-1, a protein acyl transferases (PAT) inhibitor, competitively inhibits Erf2 autopalmitoylation (WO2017011518A1; compound 13) [1].</p>Formula:C45H68N4OColor and Shape:SolidMolecular weight:681.05KRAS G12C inhibitor 46
CAS:<p>KRAS G12C inhibitor 46 is a potent inhibitor of KRAS G12C.</p>Formula:C32H33F2N7O2Color and Shape:SolidMolecular weight:585.65Calderasib
CAS:<p>Calderasib (MK-1084) is a selective KRAS G12C inhibitor (IC50 1.2 nM) with anticancer activity, usable as monotherapy or combined with PD-1 inhibitors</p>Formula:C32H31ClF2N6O4Purity:98.69%Color and Shape:SolidMolecular weight:637.08BBO-8520
CAS:<p>BBO-8520 is a dual KRASG12C inhibitor that blocks ON and OFF states, disables effector binding, suppresses signaling, and induces tumor regression.</p>Formula:C35H33F6N7O2SPurity:97.879%Color and Shape:SolidMolecular weight:729.74KRAS inhibitor-35
CAS:<p>KRAS inhibitor-35 (compound 72) is a KRAS inhibitor with an IC50 of 2 nM, utilized in tumor research.</p>Formula:C38H32F4N6O3SColor and Shape:SolidMolecular weight:728.76COTI-219
CAS:<p>COTI-219 is an oral inhibitor of KRAS with antitumor properties [1].</p>Formula:C17H18N6SColor and Shape:SolidMolecular weight:338.43pan-KRAS-IN-6
CAS:<p>Pan-KRAS-IN-6 (compound 12) is a potent pan-KRAS inhibitor, with IC50 values of 9.79 nM for Kras G12D and 6.03 nM for Kras G12V.</p>Formula:C29H30ClF3N6O3SColor and Shape:SolidMolecular weight:635.10KRASG12D-IN-3-d3
CAS:<p>KRASG12D-IN-3-d3 is the deuterium labeled KRASG12D-IN-3. KRASG12D-IN-3 (compound Z1084) is a KRASG12D inhibitor with oral bioactivity that can effectively inhibit the growth of tumor cells AGS and AsPC-1, with IC50 values of 0.38 nM and 1.23 nM, respectively.</p>Formula:C31H27D3ClF6N7O2Color and Shape:SoildMolecular weight:685.08KRAS inhibitor-21
CAS:<p>KRAS inhibitor-21 (22b) is a KRAS G12C inhibitor (IC50<0.01 μM) that can be used in cancer research.</p>Formula:C33H41N5O3Color and Shape:SolidMolecular weight:555.71Everafenib
<p>Everafenib: potent BRAF inhibitor, crosses blood-brain barrier, hinders MAPK, effective on V600EBRAF cells, outperforms other drugs in trials.</p>Formula:C20H23ClFN5O2S2Color and Shape:SolidMolecular weight:484.01Famlasertib
CAS:<p>Famlasertib is a potent inhibitor of the mitogen-activated protein kinase kinase kinase kinase (MAP4K) family, capable of penetrating the brain. It exhibits an IC50 value of 0.3 nM for HGK (MAP4K4) and 23.7 nM for MLK3.</p>Formula:C26H27ClN4OColor and Shape:SolidMolecular weight:446.972TH-Z816
CAS:<p>TH-Z816 acts as a reversible inhibitor targeting the KRAS(G12D) mutation, exhibiting an IC50 of 14 µM. This compound is utilized in cancer research [1].</p>Formula:C29H38N6OColor and Shape:SolidMolecular weight:486.65G12Si-1
<p>G12Si-1 selectively binds and inhibits K-Ras(G12S) to block oncogenic signaling and nucleotide exchange.</p>Formula:C29H32ClN5O3Color and Shape:SolidMolecular weight:534.05HPK1-IN-41
CAS:<p>HPK1-IN-41 (compound Z389) functions as an HPK1 inhibitor, exhibiting an IC50 value of 0.21 nM [1].</p>Formula:C28H33N5O2Color and Shape:SolidMolecular weight:471.59
